0% found this document useful (0 votes)
8 views31 pages

Managing Tachypnoea in ICU Patients

The patient's condition has stabilized with medical interventions but he requires ongoing monitoring for potential complications.

Uploaded by

Kushal Singh
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPT, PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
8 views31 pages

Managing Tachypnoea in ICU Patients

The patient's condition has stabilized with medical interventions but he requires ongoing monitoring for potential complications.

Uploaded by

Kushal Singh
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPT, PDF, TXT or read online on Scribd

Clinical Case Presentation

CHANGJUAN LI
CDP-CCU
15/12/2009
Basic information
 Mr. Bennett, 72 years
 Italian speaking man, Lives alone

 Independent with ALDS

 No religious belief

 Weight 80kg, height 180cm BMI 24.7


on admission
 BIBA, unwell for 1/52 with ↑SOB, HT &
worsening asthma
 O/E: alert, lethargy but comfortable
 Obs: afebrile, HR 100, BP 160/70, sats 98%
on 2 L/min O2
 JVP 3cm
 Talking in words ins/exp wheeze
Transfer to ICU
 Increasing SOB & WOB
 Tachypoenic >40 bpm, ST 120,Spo2 90% on
HM
 CXR: bilateral effusions
Past history
 Asthma/COAD  HT
 Ex-smoker >40 yrs  IHD
 Gout  ↑cholesterol
 CVA  NIDDM
 Epilepsy
 Allergy :NKDA
Diagnosis
 APO due to fluid
overload
 2o renal impairment
(↑urea 50.2, creatinine
290, ↓ eGFR 33
presumed from ACE-I
covelsyl)
What’s APO?
 fluid accumulation in the lungs.
 failure of the heart to remove fluid from the
lung circulation or a direct injury to the lung
parenchyma .
 impaired gas exchange

 pulmonary blood pressure ↑> 25 mmHg.


classical pattern of CXR in APO

                                                                    
PATHOPHYSIOLOGY of APO

 ↓ LV contractility → LV dilates & HR ↑


 ↑preload or ↓LV compliance → ↑LV diastolic pressure
 ↑ LA & PVP →Pulmonary congestion & oedema
 PCOP > 30mmHg, fluid leak →pulmonary interstitial
space→oedema
 ↓O2 → O2 exchange
 R) heart pressure ↑→ R) heart failure
PATIENT ASSESSMENT
 Ankle oedema
 Moderate respiratory distress
 Auscultation: Upper airway: clear; L & R scattered
wheeze; S3 gallop
 Appearance: anxious and distressed
 speech: short phrases
 Rhythm: prolonged expiratory phase
 Effort: increased
 Chest wall status: equal expansion
Laborotory Findings
 VBG: PH 7.38, PaCO2 41, O2 33;
 ABG: PH 7.29, PaCO2 51, O2 52;
 FBE: HB 97, WBC 17.5
 U & E: Na+ 141, K+ 5.0,Urea 14.1, Cr 179,
eGFR33, trop 0.03
 CXR: cardiomegaly, R>L basal consolidates
 ECG: ST↓ with ectopics
PaCO2↑:Gas trapping
Dyspnoea: Nursing interventions
 Observing tongue and sublingual area
 Assessing chest wall configuration
 Evaluating respiratory effort
 Instruct pt in medications, inhalers, spirometry
 Turn pt frequently to moblize secretions
 Place the patient in a comfortable position that
maximizes air exchange
 O2 therapy monitor Spo2,ABG if necessary
Dyspnoea: medical interventions
 Auscultation: bronchial BS over areas of
consolidation
 Treat the cause
 Medications: diuretics & morphine (↓preload)
 CXR
 ABG analysis
 Intubation & mechanical ventilation
Medication
 Amiodarone  Allopurinol
 Dobutamine  Amlodipine
 IVABs  Panadol osteo
 Fragmin  Methyldopa
 Frusemide  Glucosamine
 morphine+midazolam  Pantoprazole
 Predinisolone  Haloperidol
 GTN patch
Dobutamine

 synthetic catecholamine
 Selective β effects with minimal αreceptor
effects (HR & PVR)
 ↑inotropic force of myocardial contraction
 ↑CO
 ↑SV
 ↓PCWP
Dobutamine 250mg/20ml
 Dose & administration: 2.5-15mcg/kg/min.
 Titrate to effect (maximum dose 40
mcg/kg/min)
 IV infusion: 250 mg in 100ml N/Saline or
D5W (1ml/hr=2500mcg/hr=41.6mcg/min)
Dobutamine-Adverse effects
 Tachycardia, HT & VE’s -effects are dose
related
 Hypotension has occasionally been noted
 Reduction in serum K+ concentrations
 Phlebitis at site of infusion
 Occasionally- nausea, headache,angina
pectoris, dyspnea, palpitations
Hydrocortisone
 Glucocorticoid effects, e.g.
gluconeogenesis, proteolysis,
lipolysis,suppression of inflammation and
immune responses
 Mineralacorticoid effects, e.g. HT, sodium
and water retention, potassium loss
 Anti-inflammatory adrenocortical steroid
Hydrcortisone-adverse effects
 CNS: Psychotic derangement, convulsions, vertigo,
headache
 CVS:HT, salt and water retention and ↑excretion of K+ &
Ca2+, and anaphylactic reactions (rare), CHF
 GIT: Peptic ulcer, pancreatitis, abdominal distension,
ulcerative oesophagitis
 Musculoskeletal: acute myopathy, osteoporosis, impaired
wound healing, thin fragile skin
 Endo: hyperglycaemia, manifestation of diabetes mellitus,
↑requirements of hypoglycaemics and insulin
Short Synacthen Test
 Principles: serum cortisol in measured
before and after adrenal stimulation with
synacthen
Short Synacthen Test - procedure
 Collect baseline blood sample for cortisol (white
tube) and blood sample for ACTH (purple tube)
 Give 250mcg of synacthen IV (or IM)
 Take further blood samples for cortisol (white
tubes) at 30 min and 60 min intervals
 Clearly mark “30” and “60” min sample on each
path tube and pathology request
Short Synacthen Test - interpritation
 Normal- 30 or 60 min sample : > 550 and 200
above baseline level
 Borderline – 30 or 60 min sample: >550 and not
200 above baseline level (consider exogenous
steroids)
 Abnormal – 30 or 60 min sample:
<[Link] with adrenal insufficiency
Feeling safe: Psychosocial Needs of ICU Patients
 Interdependence: inadequately managed pain
may lead to feelings of powerlessness, anxiety,
and depression that in turn, heighten the patient’s
perception of pain
 Powerlessness: basic functions, including the
ability to communicate,to breath on their own, to
participate in decision making and to control
bladder and bowel function
 Sleep deprivation: sleep fragmentation
 Grief and loss
Trajectory to date
 CNS: drowsy →A & O, restless→ cooperative
 CVS: ECG & Echo normal, AF → SR, no oedema,
BP is well controlled, TTE improved
 Resp: ↑SOB → High Flow → HM; CXR
 Renal: Urea 17.3 (14.1), Crea153(179), eGFR 30
 Mobility: transfer x 2 assistance
 Transfer to the ward

You might also like